FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2982186924> ?p ?o ?g. }

• W2982186924 endingPage "S715" @default.
• W2982186924 startingPage "S715" @default.
• W2982186924 abstract "Abstract Background Invasive fungal infections (IFI) continue to affect the immunocompromised patient population. Many of these patients require antifungal prophylaxis. Voriconazole is an azole antifungal that has been utilized for preventing IFIs but does not have an approved indication for prophylaxis. Methods Adult patients admitted to Duke University Hospital from January 1, 2005 to December 31, 2015 who had received at least 2 days of systemic voriconazole as primary prophylaxis were included in this retrospective medical records review. Demographics, underlying comorbidities, adverse events, drug interactions, voriconazole blood concentrations, and microbiological data were assessed. Results Our review identified 403 patients receiving voriconazole for primary prophylaxis. 220 (55.6%) were male, 303 (75.2%) were Caucasian, and the mean age was 46.0 ± 15.7 years. 233 (57.8%) had leukemia, and 63 (15.6%) had lymphoma. 301 (74.7%) underwent hematopoietic transplant (BMT), and 45 (11.2%) had a solid-organ transplant. 176 (43.7%) patients received chemotherapy and 261 (64.8%) received immunosuppressive drugs. The mean voriconazole total daily maintenance dose was 416.1 ± 65.9 mg (5.5 ± 1.6 mg/kg/day). Patients received inpatient voriconazole for a mean of 19.5 ± 16.5 days. 371 (92.1%) patients received a concomitant interacting drug. Only 140 (43.7%) patients had therapeutic drug monitoring. The mean first voriconazole serum concentration was 1.8 ± 1.7 mg/L. 87 (21.6%) patients discontinued voriconazole prematurely; 41 (10.2% overall) of these patients had an adverse event requiring discontinuation. 5 had breakthrough fungal infections with microbiological data identifying a fungal species, which included Rhizopus spp. among others. Conclusion Voriconazole is frequently used for primary prophylaxis of IFIs and most commonly in BMT. It appears to be relatively well tolerated with some adverse side-effects (~10%) despite many potential drug–drug interactions and provides appropriate fungal coverage for many immunosuppressed patients. However, few patients had breakthrough fungal infections while receiving voriconazole. In a real-world setting, voriconazole can provide antifungal prevention in certain high-risk patients. Disclosures All authors: No reported disclosures." @default.
• W2982186924 created "2019-11-01" @default.
• W2982186924 creator A5028005649 @default.
• W2982186924 creator A5028777325 @default.
• W2982186924 creator A5074036584 @default.
• W2982186924 date "2019-10-01" @default.
• W2982186924 modified "2023-09-23" @default.
• W2982186924 title "2112. Voriconazole for Primary Prophylaxis: A Decade of Trends and Outcomes" @default.
• W2982186924 doi "https://doi.org/10.1093/ofid/ofz360.1792" @default.
• W2982186924 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6809050" @default.
• W2982186924 hasPublicationYear "2019" @default.
• W2982186924 type Work @default.
• W2982186924 sameAs 2982186924 @default.
• W2982186924 citedByCount "0" @default.
• W2982186924 crossrefType "journal-article" @default.
• W2982186924 hasAuthorship W2982186924A5028005649 @default.
• W2982186924 hasAuthorship W2982186924A5028777325 @default.
• W2982186924 hasAuthorship W2982186924A5074036584 @default.
• W2982186924 hasBestOaLocation W29821869241 @default.
• W2982186924 hasConcept C112705442 @default.
• W2982186924 hasConcept C126322002 @default.
• W2982186924 hasConcept C16005928 @default.
• W2982186924 hasConcept C197934379 @default.
• W2982186924 hasConcept C2778715236 @default.
• W2982186924 hasConcept C2779384505 @default.
• W2982186924 hasConcept C2779548794 @default.
• W2982186924 hasConcept C2780272996 @default.
• W2982186924 hasConcept C2780651595 @default.
• W2982186924 hasConcept C2780690907 @default.
• W2982186924 hasConcept C71924100 @default.
• W2982186924 hasConceptScore W2982186924C112705442 @default.
• W2982186924 hasConceptScore W2982186924C126322002 @default.
• W2982186924 hasConceptScore W2982186924C16005928 @default.
• W2982186924 hasConceptScore W2982186924C197934379 @default.
• W2982186924 hasConceptScore W2982186924C2778715236 @default.
• W2982186924 hasConceptScore W2982186924C2779384505 @default.
• W2982186924 hasConceptScore W2982186924C2779548794 @default.
• W2982186924 hasConceptScore W2982186924C2780272996 @default.
• W2982186924 hasConceptScore W2982186924C2780651595 @default.
• W2982186924 hasConceptScore W2982186924C2780690907 @default.
• W2982186924 hasConceptScore W2982186924C71924100 @default.
• W2982186924 hasIssue "Supplement_2" @default.
• W2982186924 hasLocation W29821869241 @default.
• W2982186924 hasLocation W29821869242 @default.
• W2982186924 hasOpenAccess W2982186924 @default.
• W2982186924 hasPrimaryLocation W29821869241 @default.
• W2982186924 hasRelatedWork W1403919 @default.
• W2982186924 hasRelatedWork W20047879 @default.
• W2982186924 hasRelatedWork W22026553 @default.
• W2982186924 hasRelatedWork W22110512 @default.
• W2982186924 hasRelatedWork W3217332 @default.
• W2982186924 hasRelatedWork W4424148 @default.
• W2982186924 hasRelatedWork W4839778 @default.
• W2982186924 hasRelatedWork W6962349 @default.
• W2982186924 hasRelatedWork W8430785 @default.
• W2982186924 hasRelatedWork W96634 @default.
• W2982186924 hasVolume "6" @default.
• W2982186924 isParatext "false" @default.
• W2982186924 isRetracted "false" @default.
• W2982186924 magId "2982186924" @default.
• W2982186924 workType "article" @default.